1-3 of 3
Pascal Edrich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Alex Allepuz, Justyna Fronczek-Sokol, Jens Haenig, Pascal Edrich, Adam Cuker
Journal: Blood
Blood (2023) 142 (Supplement 1): 5456.
https://doi.org/10.1182/blood-2023-180647
Published: 2023
Journal Articles

Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model

Francois-Xavier Mahon, MD PhD Professor, An Tran-Duy, Raechelle G. Ocampo, David Ray, PharmD, MBA, Estella Mendelson, BSRN, MBA, Aby Buchbinder, Pascal Edrich, Sonya J. Snedecor, PhD, Giuseppe Saglio
Journal: Blood
Blood (2015) 126 (23): 5154.
https://doi.org/10.1182/blood.V126.23.5154.5154
Published: 2015
Journal Articles

Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase

Giuseppe Saglio, Sonya J. Snedecor, PhD, Xiang Ji, Ming-Hui Tai, BPharm, MHPA, PhD, David Ray, PharmD, MBA, Estella Mendelson, BSRN, MBA, Aby Buchbinder, Pascal Edrich, Francois-Xavier Mahon, MD PhD Professor
Journal: Blood
Blood (2015) 126 (23): 1579.
https://doi.org/10.1182/blood.V126.23.1579.1579
Published: 2015